# The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia

> **NCT07362355** · PHASE2 · RECRUITING · sponsor: **Jiangsu HengRui Medicine Co., Ltd.** · enrollment: 340 (estimated)

## Conditions studied

- Primary Gout and Hyperuricemia

## Interventions

- **DRUG:** SHR4640 ；Febuxostat
- **DRUG:** SHR4640 ; Febuxostat
- **DRUG:** SHR4640
- **DRUG:** SHR4640
- **DRUG:** Febuxostat

## Key facts

- **NCT ID:** NCT07362355
- **Lead sponsor:** Jiangsu HengRui Medicine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-02-09
- **Primary completion:** 2027-07
- **Final completion:** 2027-07
- **Target enrollment:** 340 (ESTIMATED)
- **Last updated:** 2026-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07362355

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07362355, "The Efficacy and Safety of SHR4640 Tablet Combined With 40 mg Febuxostat Tablets in the Treatment of Primary Gout and Hyperuricemia". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT07362355. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*